ABG
EPRX

Ally Bridge Group’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Ally Bridge Group’s Portfolio EPRX Stock Details EPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.78M Buy
660,375
+262,480
+66% +$2.11M 3.86% 13
2025
Q4 		$3M Sell
397,895
-517,105
-57% -$3.19M 3.13% 12
2025
Q3 		$5.4M Buy
+915,000
New +$4.98M 3.29% 12

Other funds holding EPRX

BGC
Beutel, Goodman & Co Toronto, Ontario, Canada $14.8B AUM 15.12% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
SC
Scotia Capital Toronto, Ontario, Canada $24.3B AUM 29.21% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Ally Bridge Group's EPRX Position: Q1 2026 in Review

Ally Bridge Group increased its Eupraxia Pharmaceuticals (EPRX) stake by 66% in Q1 2026, buying an estimated $2.11M and bringing the position to 660,375 shares worth $4.78M. The position accounts for 3.86% of the portfolio, ranked #13.

Ally Bridge Group first reported a position in EPRX in Q3 2025 and has held it in 3 quarters since. The position peaked at $5.4M in Q3 2025. 54 funds tracked by Wall St. Rank hold EPRX as of Q1 2026.

  • Ally Bridge Group held 660,375 shares of Eupraxia Pharmaceuticals worth $4.78M as of Q1 2026.
  • Ally Bridge Group bought 262,480 Eupraxia Pharmaceuticals shares in Q1 2026, an estimated $2.11M.
  • Eupraxia Pharmaceuticals made up 3.86% of Ally Bridge Group's portfolio in Q1 2026, its #13 holding.
  • Ally Bridge Group first reported a position in Eupraxia Pharmaceuticals in Q3 2025 and has held it in 3 quarters since.
  • Ally Bridge Group's Eupraxia Pharmaceuticals position peaked at $5.4M in Q3 2025.
  • 54 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q1 2026.

Based on Ally Bridge Group's 13F filing for Q1 2026, filed 18 May 2026.